Journal of Controlled Release : Official Journal of the Controlled Release Society 1999: Vol 57 Index

5 Pages·1999·1 MB·English

journal of
controlled
release
Journal of Controlled Release 57 (1999) 315-316
Author Index Volume 57 (1999)
Abd El-Ghaffar, M.A., see Helaly, F.M. (57) 1 Fassihi, R., see Yang, L. (57) 215
Abu Fara, D., see Al-Musa, S. (57) 223 Ferry, D.R., see Julyan, P.J. (57) 281
Ahmed, A.A., see Helaly, F.M. (57) 1 Ford, J.L., see Velasco, MXN. (57) 75
Akamatsu, K., see Yura, H. (57) 87 Frucht-Pery, J., see Klang, S.H. (57) 19
Al-Musa, S., Abu Fara, D. and Badwan, A.A., Evaluation of
parameters involved in preparation and release of drug loaded Gadras, C., Santaella, C. and Vierling, P., Improved stability of
in crosslinked matrices of alginate (57) 223 highly fluorinated phospholipid-based vesicles in the presence
Anderson, D., see Julyan, P.J. (57) 281 of bile salts (57) 29
Anderson, J.M. and Langone, J.J., Issues and perspectives on the
Garcia, M.J., see Macias, R.I.R. (57) 161
biocompatibility and immunotoxicity evaluation of implanted Garnett, M.C., see Govender, T. (57) 171
controlled release systems (57) 107 Gibbes, D.C., see Thombre, A.G. (57) 65
Anseth, K.S., see Lu, S. (57) 291 Gorner, T., Gref, R., Michenot, D., Sommer, F., Tran, M.N. and
Anwar, H., see Owusu-Ababio, G. (57) 151 Dellacherie, E., Lidocaine-loaded biodegradable nanospheres.
Atterholt, C.A., Delwiche, M.J., Rice, R.E. and Krochta, J.M., I. Optimization of the drug incorporation into the polymer
Controlled release of insect sex pheromones from paraffin wax
matrix (57) 259
and emulsions (57) 233 Govender, T., Stolnik, S., Garnett, M.C., Illum, L. and Davis, S.S.,
PLGA nanoparticles prepared by nanoprecipitation: drug
Badwan, A.A., see Al-Musa, S. (57) 223 loading and release studies of a water soluble drug (57) 171
Benita, S., see Kiang, S.H. (57) 19 Gref, R., see Gorner, T. (57) 259
Bodmeier, R., see Schmidt, C. (57) 115
Boivin, C.M., see Julyan, P.J. (57) 281
Hamashima, T., see Yura, H. (57) 87
Hashida, M., see Yura, H. (57) 87
Cardinal, J.R., see Thombre, A.G. (57) 55
Hatano, H., see Ishibashi, T. (57) 45
Cardinal, J.R., see Thombre, A.G. (57) 65
Helaly, F.M., Ahmed, A.A. and Abd El-Ghaffar, M.A., Natural
Christodoulou, C., see Julyan, P.J. (57) 281
rubber base matrix containing Calendula officinalis plant as a
source of molluscicdal saponin (57) |
Daryani, S., see Julyan, P.J. (57) 281
Herbig, S.M., see Thombre, A.G. (57) 55
David, M., see Julyan, P.J. (57) 281
Hesslewood, S., see Julyan, P.J. (57) 281
Davis, S.S., see Govender, T. (57) 171
Dellacherie, E., see Gorner, T. (57) 259
Illum, L., see Govender, T. (57) 171
Delwiche, M.J., see Atterholt, C.A. (57) 233
Ishibashi, T., Hatano, H., Kobayashi, M., Mizobe, M. and
DeNoto, A.R., see Thombre, A.G. (57) 55
Yoshino, H., In vivo drug release behavior in dogs from a new
DeNoto, A.R., see Thombre, A.G. (57) 65
colon-targeted delivery system (57) 45
Doran, J., see Julyan, P.J. (57) 281
Du, B., see Zhuo, R.X. (57) 249
Dunmire, E.N., Plenys, A.M. and Katz, D.F., Spectrophotometric Julyan, P.J., Seymour, L.W., Ferry, D.R., Daryani, S., Boivin,
analysis of molecular transport in gels (57) 127 C.M., Doran, J., David, M., Anderson, D., Christodoulou, C.,
Young, A.M., Hesslewood, S. and Kerr, D.J., Preliminary
Ehtezazi, T., Washington, C. and Melia, C.D., Determination of clinical study of the distribution of HPMA copolymers bearing
the internal morphology of poly (D,L-lactide) microspheres doxorubicin and galactosamine (57) 281
using stereological methods (57) 301
Eichler, H.G., see Luftensteiner, C.P. (57) 35 Katz, D.F., see Dunmire, E.N. (57) 127
El-Mir, M-Y., see Macias, R.I.R. (57) 161 Kerr, D.J., see Julyan, P.J. (57) 281
Eshraghi, J., see Yang, L. (57) 215 Kim, C.-j., see Konar, N. (57) 141
PII: S0168-3659(99)00002-4
316 Author Index Volume 57 (1999)
Klang, S.H., Siganos, C.S., Benita, S. and Frucht-Pery, J., Rogers, J., see Owusu-Ababio, G. (57) 151
Evaluation of a positively charged submicron emulsion of Rowe, P., see Velasco, MXN. (57) 75
piroxicam on the rabbit corneum healing process following
alkali burn (57) 19 Samuel, J., see Wang, D. (57) 9
Kobayashi, M., see Ishibashi, T. (57) 45 Santaella, C., see Gadras, C. (57) 29
Koerten, H.K., see Marttin, E. (57) 205 Schacht, E., see Soyez, H. (57) 187
Konar, N. and Kim, C.-j., Drug release from drug-polyanion Schmidt, C. and Bodmeier, R., Incorporation of polymeric
complex tablets: poly(acrylamido-2-methy]-|-propanesulfonate nanoparticles into solid dosage forms (57) 115
sodium -co- methyl methacrylate) (57) 141 Schwendenwein, I., see Luftensteiner, C.P. (57) 35
Krochta, J.M., see Atterholt, C.A. (57) 233 Serrano, M.A., see Macias, R.I.R. (57) 161
Kwon, G.S., see Wang, D. (57) 9 Seymour, L.W., see Julyan, P.J. (57) 281
Seymour, L.W., see Soyez, H. (57) 187
Langone, J.J., see Anderson, J.M. (57) 107 Siganos, C.S., see Klang, S.H. (57) 19
Lee, K.H., see Oh, J.E. (57) 269 Smith, K.L., see Thombre, A.G. (57) 55
Lu, S. and Anseth, K.S., Photopolymerization of multilaminated Sommer, F., see Gorner, T. (57) 259
poly(HEMA) hydrogels for controlled release (57) 291 Soyez, H., Seymour, L.W. and Schacht, E., Macromolecular
Lu, Z.R., see Zhuo, R.X. (57) 249 derivatives of N,N-di-(2-chloroethyl)-4-phenylene diamine
Luftensteiner, C.P., Schwendenwein, I., Paul, B., Eichler, H.G. mustard. 2. In vitro cytotoxicity and in vivo anticancer efficacy
and Viernstein, H., Evaluation of mitoxantrone-loaded al- (57) 187
bumin microspheres following intraperitoneal administration Spies, F., see Marttin, E. (57) 205
to rats (57) 35 Stolnik, S., see Govender, T. (57) 171
Macias, R.I.R., El-Mir, M.Y., Monte, M.J., Serrano, M.A., Garcia, Takakura, Y., see Yura, H. (57) 87
M.J. and Marin, J.J.G., Cholephilic characteristics of a new Thombre, A.G., Cardinal, J.R., DeNoto, A.R. and Gibbes, D.C.,
cytostatic complex of cisplatin with glycocholate (Bamet-R2) Asymmetric membrane capsules for osmotic drug delivery II.
(57) 161 In vitro and in vivo drug release performance (57) 65
Majid Khan, G. and Zhu, J.-B., Studies on drug release kinetics Thombre, A.G., Cardinal, J.R., DeNoto, A.R., Herbig, S.M. and
from ibuprofen—carbomer hydrophilic matrix tablets: influence Smith, K.L., Asymmetric membrane capsules for osmotic drug
of co-excipients on release rate of the drug (57) 197 delivery. I. Development of a manufacturing process (57) 55
Marin, J.J.G., see Macias, R.I.R. (57) 161 Tran, M.N., see Gorner, T. (57) 259
Marttin, E., Verhoef, J.C., Spies, F., van der Meulen, J., Nagel-
kerke, J.F., Koerten, H.K. and Merkus, F.W.H.M., The effect van der Meulen, J., see Marttin, E. (57) 205
of methylated B-cyclodextrins on the tight junctions of the rat Velasco, MNV., Ford, J.L., Rowe, P. and Rajabi-Siahboomi, A.R.,
nasal respiratory epithelium. Electron microscopic and con- Influence of drug:hydroxypropylmethylcellulose ratio, drug
focal laser scanning microscopic visualization studies (57) 205 and polymer particle size and compression force on the release
Melia, C.D., see Ehtezazi, T. (57) 301 of diclofenac sodium from HPMC tablets (57) 75
Merkus, F.W.H.M., see Marttin, E. (57) 205 Verhoef, J.C., see Marttin, E. (57) 205
Michenot, D., see Gorner, T. (57) 259 Vierling, P., see Gadras, C. (57) 29
Mizobe, M., see Ishibashi, T. (57) 45 Viernstein, H., see Luftensteiner, C.P. (57) 35
Monte, M.J., see Macias, R.I.R. (57) 161
Wang, D., Robinson, D.R., Kwon, G.S. and Samuel, J., Encapsula-
Nagelkerke, J.F., see Marttin, E. (57) 205 tion of plasmid DNA in biodegradable poly(p,L-lactic-co-
Nam, Y.S., see Oh, J.E. (57) 269 glycolic acid) microspheres as a novel approach for immuno-
Nishikawa, M., see Yura, H. (57) 87 gene delivery (57) 9
Washington, C., see Ehtezazi, T. (57) 301
Oh, J.E., Nam, Y.S., Lee, K.H. and Park, T.G., Conjugation of
Yang, L., Eshraghi, J. and Fassihi, R., A new intragastric delivery
drug to poly(p,L-lactic-co-glycolic acid) for controlled release
system for the treatment of Helicobacter pylori associated
from biodegradable microspheres (57) 269
gastric ulcer: in vitro evaluation (57) 215
Owusu-Ababio, G., Rogers, J. and Anwar, H., Effectiveness of
ciprofloxacin microspheres in eradicating bacterial biofilm Yoshimura, N., see Yura, H. (57) 87
(57) 151 Yoshino, H., see Ishibashi, T. (57) 45
Young, A.M., see Julyan, P.J. (57) 281
Yura, H., Yoshimura, N., Hamashima, T., Akamatsu, K.,
Park, T.G., see Oh, J.E. (57) 269
Nishikawa, M., Takakura, Y. and Hashida, M., Synthesis and
Paul, B., see Luftensteiner, C.P. (57) 35
pharmacokinetics of a novel macromolecular prodrug of
Plenys, A.M., see Dunmire, E.N. (57) 127
Tacrolimus (FK506), FK506—dextran conjugate (57) 87
Rajabi-Siahboomi, A.R., see Velasco, MV. (57) 75 Zhu, J.-B., see Majid Khan, G. (57) 197
Rice, R.E., see Atterholt, C.A. (57) 233 Zhuo, R.X., Du, B. and Lu, Z.R., In vitro release of 5-fluorouracil
Robinson, D.R., see Wang, D. (57) 9 with cyclic core dendritic polymer (57) 249
journal of
controlled
ol YN
release
ELSEoe VeIelE] Ra
Journal of Controlled Release 57 (1999) 317-318
Subject Index Volume 57 (1999)
Albumin microspheres, (57) 35 Electron microscopy, (57) 205
Alkali burn, (57) 19 Encapsulation, (57) 259
Anticancer efficacy, (57) 187 Erosion, (57) 141
Antigen delivery, (57) 9 Eudragit°E, (57) 45
Asialoglycoprotein receptor, (57) 281 FK506—dextran conjugate, (57) 87
Asymmetric membrane capsule(s), (57) 55, (57) 65 Film crosslinking, (57) 223
Bacterial biofilm, (57) 151 Flocculation, (57) 115
Beagle dog, (57) 45 Fluorinated liposomes, (57) 29
Bile acid, (57) 161 Fluorinated phospholipids, (57) 29
Biocompatibility, (57) 107 5-Fluorouracil, (57) 249
Biodistribution, (57) 87 Food effect, (57) 45
Calendula officinalis, (57) 1 Galactose, (57) 281
Cancer, (57) 161 Gastric emptying, (57) 45
Carbopol® 934P and 971P, (57) 197 Gels, (57) 127
Chemotherapy, (57) 161 HPMA copolymers, (57) 281
Ciprofloxacin, (57) 151 HPMC, (57) 75
Co-excipients, (57) 197 HPMC”®-AS, (57) 45
Colloidal carriers, (57) 115 Hard gelatin capsule, (57) 45
Colon-targeted delivery, (57) 45 Ibuprofen, (57) 197
Complex, (57) 141 Imaging, (57) 281
Compression force, (57) 75 Immunotoxicity, (57) 107
Confocal laser scanning microscopy, (57) 205 In vivo, (57) 35
Conjugation, (57) 269 In vitro and in vivo release, (57) 65
Controlled drug release, (57) 215 In vitro release profile, (57) 127
Controlled release, (57) 107, (57) 141, (57) 223, (57) 233, (57) In vitro release, (57) 171
259 Intragastric drug delivery, (57) 215
Cyclodextrins, (57) 205 Intraperitoneal chemotherapy, (57) 35
Cytotoxicity, (57) 187 Kidney, (57) 161
DNA delivery, (57) 9 Lidocaine, (57) 259
Degradation-controlled, (57) 269 Liver, (57) 161
Dendrimer, (57) 249 Manual and semiautomatic manufacture, (57) 55
Detergent, (57) 29 Mating disruption, (57) 233
Dextran, (57) 87 Matrix tablets, (57) 197
Diclofenac sodium, (57) 75 Metal, (57) 161
Diffusion- and swelling-controlled release, (57) 197 Membranes, (57) 29
Diffusion-controlled release, (57) 291 Michael addition, (57) 249
Diffusion, (57) 127 Microsphere(s), (57) 9, (57) 269, (57) 301
Dissociation, (57) 141 Mitoxantrone, (57) 35
Doxorubicin, (57) 281 Modeling, (57) 291
Drug delivery mechanism, (57) 65 Multivariate confidence ellipses, (57) 127
Drug incorporation, (57) 171 Nanoparticles, (57) 115, (57) 171, (57) 259
Drug release, (57) 223 Nanoprecipitation, (57) 171
Drug:HPMC ratio, (57) 75 Nasal drug delivery, (57) 205
PII: S0168-3659(99)00003-6
318 Subject Index Volume 57 (1999)
Natural rubber, (57) 1 Re-epithelization, (57) 19
N,N-Di-(2-chloroethyl)-4-phenylene diamine mustard, (57) 187 Redispersibility, (57) 115
Nonuniform initial drug loading, (57) 291 Release, (57) 249
Oral dosage forms, (57) 115 Robotic process, (57) 55
Oriental fruit moth, (57) 233 Saponin, (57) 1
Osmotic delivery, (57) 65 Sodium alginate, (57) 223
Paraffin, (57) 233 Sodium taurodihydrofusidate, (57) 205
Particle size, (57) 75 Specific surface area, (57) 301
Permeability, (57) 29 Stereology, (57) 301
Pharmacokinetics, (57) 87, (57) 161 Sulfonate, (57) 141
Phase inversion, (57) 55 Sustained release, (57) 35, (57) 151
Pheromone, (57) 233 Tacrolimus (FK506), (57) 87
Photopolymerization, (57) 291 1,4,7,10-Tetraazacyclododecane, (57) 249
Piroxicam, (57) 19 Tetracycline and metronidazole, (57) 215
Platinum, (57) 161 Tight junctions, (57) 205
PLGA, (57) 171, (57) 269 Treatment of Helicobacter pylori, (57) 215
Poly (p,p-lactide), (57) 301 Triple therapy, (57) 215
Poly(p,L-lactic acid), (57) 259 Tumor, (57) 161
Poly(p,L-lactic-co-glycolic acid), (57) 9 Tumour-associated enzymes, (57) 187
Poly(L-lactic acid), (57) 151 UV spectrophotometry, (57) 127
Poly[N°-(2-hydroxyethyl)-L-glutamine] prodrug, (57) 187 Ulceration process, (57) 19
Polyelectrolyte, (57) 141 Vaccines, (57) 9
Polymer dispersions, (57) 115 Vesicles, (57) 29
Polymer matrices, (57) 223 Vulcanizate, (57) 1
Pore size distribution, (57) 301 Zero-order release, (57) 269
Porosity, (57) 301
Positively charged emulsion, (57) 19
Prodrug, (57) 87